Retatrutide 10 mg – Triple-Agonist Therapy (Phase 3)
🔹 Mechanism of Action
Retatrutide is a first-in-class triple-agonist. It targets three key hormone receptors in the body:
-
GLP-1 (glucagon-like peptide-1)
-
GIP (glucose-dependent insulinotropic polypeptide)
-
Glucagon receptors
This combination may offer several benefits:
-
Reduced appetite (GLP-1)
-
Increased fat burning and energy use (glucagon)
-
Better insulin sensitivity (GIP)
🔹 Clinical Trial Results (Phase 2 Study)
In a 24-week study, Retatrutide 10 mg showed strong results compared to Tirzepatide 10 mg:
-
Weight loss: 18.2% vs. 14.9% total body weight
-
A1c reduction: 1.8% vs. 1.5%
-
Waist reduction: 6.2 inches vs. 5.1 inches
-
Nausea rate: 32% vs. 28%
These results suggest improved weight loss and metabolic outcomes.
🔹 Dosing and Administration
Retatrutide is given as a weekly injection.
Typical dose schedule:
-
Weeks 1–4: 2 mg
-
Weeks 5–8: 4 mg
-
Weeks 9–12: 6 mg
-
Weeks 13–16: 8 mg
-
Week 17+: 10 mg (maintenance)
How to use:
-
Inject under the skin (abdomen or thigh)
-
Use the same day each week
-
Rotate injection sites to reduce irritation
🔹 Key Benefits of Retatrutide peptide buy online
Retatrutide may offer advantages over existing treatments:
Greater weight loss
-
Up to 3–5% more weight loss than tirzepatide
-
Higher fat loss while preserving lean muscle
Improved metabolic health
-
Reduced liver fat
-
Increased resting metabolic rate
-
Better blood sugar control
Flexible dosing (under study)
-
Monthly dosing may be possible in the future
🔹 Safety and Side Effects of Retatrutide peptide buy online
Common side effects include:
-
Nausea
-
Diarrhea
-
Mild increase in heart rate
-
Injection site reactions
These effects are usually mild and may improve over time.
Important safety concerns:
-
Possible thyroid tumor risk (seen in early studies)
-
Risk of pancreatitis
Always consult a healthcare provider before use.
🔹 Who May Benefit
Retatrutide may be suitable for:
-
People with BMI ≥30 (obesity)
-
Patients needing significant weight loss (>15%)
-
Individuals who did not respond to other GLP-1 therapies
Not recommended for:
-
History of thyroid cancer
-
Multiple endocrine neoplasia syndrome type 2
-
Severe kidney or liver disease
🔹 Monitoring During Treatment
Doctors may recommend regular checks, including:
-
Weight and BMI tracking
-
Blood sugar and metabolic panels
-
Thyroid and pancreatic markers
-
Heart health monitoring
🔹 Cost and Availability
-
Expected cost: $1,200–$1,500 per month (if approved)
-
Possible uses: obesity, type 2 diabetes, and liver disease
Retatrutide is still under review by the U.S. Food and Drug Administration and is not yet approved.
🔹 Comparison With Other Treatments
| Feature | Retatrutide 10 mg | Tirzepatide 15 mg | Semaglutide 2.4 mg |
|---|---|---|---|
| Targets | GLP-1, GIP, Glucagon | GLP-1, GIP | GLP-1 |
| Weight Loss (24 weeks) | 18.2% | 14.9% | 12.4% |
| A1c Reduction | 1.8% | 1.7% | 1.5% |
| Hypoglycemia Risk | Low | Low | Low |
🔹 Ongoing Research
Current Phase 3 studies are exploring:
-
Long-term weight loss (72 weeks)
-
Heart health outcomes
-
Liver disease (NASH) improvements
-
Blood pressure and metabolic effects
⚠️ Important Note
Retatrutide is an investigational medication and is not yet approved for public use. Approval will depend on ongoing clinical trial results. Retatrutide peptide buy online




Reviews
There are no reviews yet.